Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19

• Status: Not yet recruiting
• Trial end date: 2021-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Study into the effects of daily use of metformin and low-dose naltrexone (LDN) for 4 weeks to reduce symptoms, disease severity, and recovery time from COVID-19.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AgelessRx
• Treatments: Metformin; Naltrexone

Criteria

Inclusion Criteria:

• Age 30-70

• Any sex

• Any ethnicity

• Adequate cognitive function to be able to give informed consent

• Technologically competent to complete web forms and perform video calls with the PI

• Positive PCR (polymerase chain reaction) test result for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) within the last 10 days

• At least two COVID-19 symptoms as assessed by laboratory or patient self-reporting started within the last 3 days

• Willing to fill out regular questionnaires

• Willing to take metformin and LDN

Exclusion Criteria:

• Clinically significant hepatic, renal, or cardiac impairment (as determined by previous clinical judgement)

• Hypoglycemia

• Currently on drugs for COVID-19

• Hospitalization for COVID-19

• (Suspected) pregnancy or breastfeeding

• Active cancer

• Uncontrolled mental health issues

• On any medication with major interactions with metformin or LDN

• Taking opioid analgesics, or being treated for opioid addiction/recovery

• Opioid dependence or withdrawal syndrome

• Known sensitivity to metformin or naltrexone

• Current users of metformin or naltrexone